Due to the unique mechanical properties of the low molecular weight gels, they break when passed through an in-line syringe filter releasing the fully functional protein cargo with no need for any chemical triggers and the effect is instantaneous. Due to the extended supramolecular network formed by the gelators, all the gel components (e.g., excipients) are retained in the filter, meaning only protein and buffer is released. To be very clear, this means only pure protein in buffer is delivered, unlike all competing technologies which lead to protein containing novel, often untested, excipients which would then be delivered to a patient, and hence face regulatory and safety barriers to use. This is also a benefit over freeze-dried or frozen formulations requiring no on-use reconstitution, nor energy-intensive ultra-low freezers, respectively. We have therefore provided a new scalable means of storing, transporting, and safely using biologics, affording a simple and effective strategy to deliver biologic therapies to low resource settings where they are needed most.